Unicycive CFO granted 169,500 RSUs

Townsend John reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Townsend John reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics CFO John Townsend received a grant of 169,500 restricted stock units (RSUs) tied to the company’s common stock. This is a stock-based compensation award, not an open-market share purchase or sale.

According to the footnote, 23,542 shares vest upon grant, and an additional 4,708 shares vest over 31 months beginning on June 1, 2026, as long as he continues to serve at the company. Following this award, Townsend is shown as directly holding 169,500 RSUs, aligning his compensation more closely with the company’s future stock performance.

Insider Trade Summary

Grant/Award: 169,500 shares

Grant/Award 1 txn

Insider Townsend John

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	169,500	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 169,500 contracts (Direct)

Footnotes (1)

1. F1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Key Figures

RSU grant size: 169,500 RSUs Immediate vesting portion: 23,542 shares Monthly vesting tranche: 4,708 shares +2 more

5 metrics

RSU grant size 169,500 RSUs Restricted Stock Unit award to CFO John Townsend

Immediate vesting portion 23,542 shares Shares vest upon grant under RSU Award

Monthly vesting tranche 4,708 shares Vests over 31 months beginning June 1, 2026

Total RSUs after transaction 169,500 units Total restricted stock units following the grant

Transaction date May 14, 2026 Date of RSU grant to CFO

Key Terms

Restricted Stock Unit, RSU Award, vest, common stock

4 terms

Restricted Stock Unit financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU Award financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

vest financial

"23,542 shares vest upon grant and 4,708 shares vest over 31 months"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

common stock financial

"payable solely in common stock of the Issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Unicycive Therapeutics (UNCY) CFO John Townsend receive in this Form 4/A?

The CFO received a grant of 169,500 restricted stock units (RSUs) tied to Unicycive Therapeutics common stock. This represents stock-based compensation rather than an open-market transaction, aligning part of his pay with future share performance.

How many Unicycive (UNCY) RSUs vest immediately for the CFO?

The filing states that 23,542 shares vest upon grant from the CFO’s RSU award. Immediate vesting gives him an initial stake right away, while the remaining units follow a longer vesting schedule tied to continued service with the company.

What is the vesting schedule for the remaining Unicycive (UNCY) RSUs?

The footnote explains that 4,708 shares vest over 31 months starting June 1, 2026. These vesting conditions require the CFO to maintain continued service with Unicycive Therapeutics for the shares to be delivered over time.

Is the Unicycive (UNCY) CFO Form 4/A an open-market stock purchase or sale?

No, the transaction is a grant of restricted stock units, not an open-market buy or sell. The Form 4/A records compensation-related equity awarded to the CFO, which will convert into common shares as the vesting conditions are met.

How many Unicycive (UNCY) RSUs does the CFO hold after this award?

After the grant, total RSUs following the transaction are reported as 169,500 units. These RSUs represent a right to receive common stock in the future, subject to the specified vesting terms and continued employment with Unicycive Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend John

(Last) (First) (Middle)

C/O UNICYCIVE THERAPEUTICS, INC.

1975 W. EL CAMINO REAL, SUITE 204

(Street)

MOUNTAIN VIEW CALIFORNIA 94040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/20/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	05/14/2026		A		169,500		(1)	(1)	Common Stock	169,500	$0	169,500	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

	/s/ John Townsend	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)